With the latest hopes of licensing its hypertension drug Tryvio falling through, Idorsia has moved to claw back $100 million in upcoming development costs from a separate deal with Viatris.

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48 ...

Despite operational successes, Viatris faced a significant 71% drop in GAAP net earnings due to international market pressures. Viatris delivered a mixed quarter, topping earnings expectations but ...

CANONSBURG, Pa. (AP) — CANONSBURG, Pa. (AP) — Viatris Inc (VTRS) on Thursday reported a loss of $516.5 million in its fourth quarter. The Canonsburg, Pennsylvania-based company said it had a ...